Emergency delivery in case of suspected placenta accreta spectrum: Can it be predicted?

US markers antenatal bleeding cesarean section placenta accreta spectrum predictive model

Journal

Acta obstetricia et gynecologica Scandinavica
ISSN: 1600-0412
Titre abrégé: Acta Obstet Gynecol Scand
Pays: United States
ID NLM: 0370343

Informations de publication

Date de publication:
11 Sep 2024
Historique:
revised: 30 06 2024
received: 25 01 2024
accepted: 10 07 2024
medline: 11 9 2024
pubmed: 11 9 2024
entrez: 11 9 2024
Statut: aheadofprint

Résumé

The main goal of placenta accreta spectrum (PAS) screening is to enable delivery in an expert center in the presence of an experienced team at an appropriate time. Our study aimed to identify independent risk factors for emergency deliveries within the IS-PAS 2.0 database cohort and establish a multivariate predictive model. A retrospective analysis of prospectively collected PAS cases from the IS-PAS database between January 2020 and June 2022 by 23 international expert centers was performed. All PAS cases (singleton and multiple pregnancies) managed according to local protocols were included. Individuals with emergent delivery were identified and compared to those with scheduled delivery. A multivariate analysis was conducted to identify the possible risk factors for emergency delivery and was used to establish a predictive model. Maternal outcomes were compared. Overall, 315 women were included in the study. Of these, 182 participants (89 with emergent and 93 with scheduled delivery) were included in the final analysis after exclusion of those with unsuspected PAS antenatally or who lacked information about the urgency of delivery. Gestational age at delivery was higher in the scheduled group (34.7 vs. 32.9, p < 0.001). Antenatal bleeding (OR 2.9, p = 0.02) and a placenta located over a uterine scar (OR 0.38, p = 0.001) were the independent predictive factors for emergent delivery (AUC 0.68). Ultrasound (US) markers: loss of clear zone (p = 0.001), placental lacunae (p = 0.01), placental bulge (p = 0.02), and presence of bridging vessels (p = 0.02) were more frequently documented in the scheduled group. None of these markers improved the predictive values of the model. Higher PAS grades were identified in the scheduled group (p = 0.01). There were no significant differences in maternal outcomes. Antenatal bleeding and the placental location away from the uterine scar remained the most significant predictors for emergent delivery among patients with PAS, even when combining more predictive risk factors, including US markers. Based on these results, patients who bleed antenatally may benefit from transfer to an expert center, as we found no differences in maternal outcomes between groups delivered in expert centers. Earlier-scheduled delivery is not supported due to the low predictive value of our model.

Identifiants

pubmed: 39258735
doi: 10.1111/aogs.14931
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Investigateurs

Petra Pateisky (P)
Johannes J Duvekot (JJ)
Hubert Huras (H)
Katarzyna Kawka-Paciorkowska (K)
Maddalena Morlando (M)
Frederic Chantraine (F)
Pavel Calda (P)
Gita Strindfors (G)
Pedro Viana Pinto (PV)
Anja Bluth (A)
Monica Maria Siaulys (MM)
Ozhan M Turan (OM)
Ammar Al Naimi (A)
Andrew Rubenstein (A)
Albaro Jose Nieto-Calvache (AJ)

Informations de copyright

© 2024 The Author(s). Acta Obstetricia et Gynecologica Scandinavica published by John Wiley & Sons Ltd on behalf of Nordic Federation of Societies of Obstetrics and Gynecology (NFOG).

Références

Jauniaux E, Chantraine F, Silver RM, Langhoff‐Roos J. FIGO placenta Accreta diagnosis and management expert consensus panel. FIGO consensus guidelines on placenta accreta spectrum disorders: epidemiology. Int J Gynaecol Obstet. 2018;140:265‐273.
Jauniaux E, Silver RM, Matsubara S. The new world of placenta accreta spectrum disorders. Int J Gynaecol Obstet. 2018;140:259‐260.
Ali H, Chandraharan E. Etiopathogenesis and risk factors for placental accreta spectrum disorders. Best Pract Res Clin Obstet Gynaecol. 2021;72:4‐12.
ADoPAD (Antenatal Diagnosis of Placental Attachment Disorders) Study Group. Determinants of emergency cesarean delivery in pregnancies complicated by placenta previa with or without placenta accreta spectrum disorder: analysis of ADoPAD cohort. Ultrasound Obstet Gynecol. 2024;63:243‐250.
Collins SL, Ashcroft A, Braun T, et al. Proposal for standardized ultrasound descriptors of abnormally invasive placenta (AIP). Ultrasound Obstet Gynecol. 2016;47:271‐275.
Morel O, van Beekhuizen HJ, Braun T, et al. Performance of antenatal imaging to predict placenta accreta spectrum degree of severity. Acta Obstet Gynecol Scand. 2021;10(Suppl 1):21‐28.
Jauniaux E, Alfirevic Z, Bhide AG, et al. Placenta Praevia and placenta Accreta: diagnosis and management: green‐top guideline No. 27a. BJOG. 2019;126:e1‐e48.
Collins SL, Alemdar B, van Beekhuizen HJ, et al. Evidence‐based guidelines for the management of abnormally invasive placenta: recommendations from the International Society for Abnormally Invasive Placenta. Am J Obstet Gynecol. 2019;220:511‐526.
Morlando M, Schwickert A, Stefanovic V, et al. Maternal and neonatal outcomes in planned versus emergency cesarean delivery for placenta accreta spectrum: a multinational database study. Acta Obstet Gynecol Scand. 2021;100(Suppl 1):41‐49.
Braun T, van Beekhuizen HJ, Morlando M, Morel O, Stefanovic V. International Society for Placenta Accreta Spectrum (IS‐PAS). Developing a database for multicenter evaluation of placenta accreta spectrum. Acta Obstet Gynecol Scand. 2021;100(Suppl 1):7‐11.
Thang NM, Anh NTH, Thanh PH, Linh PT, Cuong TD. Emergent versus planned delivery in patients with placenta accreta spectrum disorders: a retrospective study. Medicine. 2021;100:e28353.
Zhao H, Li X, Yang S, et al. Risk factors of emergency cesarean section in pregnant women with severe placenta accreta spectrum: a retrospective cohort study. Front Med. 2023;10:1195546.
Bowman ZS, Manuck TA, Eller AG, Simons M, Silver RM. Risk factors for unscheduled delivery in patients with placenta accreta. Am J Obstet Gynecol. 2014;210:241.e1‐241.e2416.
Wang Y, Zeng L, Niu Z, et al. An observation study of the emergency intervention in placenta accreta spectrum. Arch Gynecol Obstet. 2019;299:1579‐1586.
Jauniaux E, Ayres‐de‐Campos D, Langhoff‐Roos J, Fox KA, Collins S. FIGO placenta Accreta diagnosis and management expert consensus panel. FIGO classification for the clinical diagnosis of placenta accreta spectrum disorders. Int J Gynaecol Obstet. 2019;146:20‐24.
Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33:1‐22.
Fishman SG, Chasen ST. Risk factors for emergent preterm delivery in women with placenta previa and ultrasound findings suspicious for placenta accreta. J Perinat Med. 2011;39:693‐696.
Jauniaux E, Jurkovic D, Hussein AM, Burton GJ. New insights into the etiopathology of placenta accreta spectrum. Am J Obstet Gynecol. 2022;227:384‐391.
Jauniaux E, Bhide A, Kennedy A, et al. FIGO consensus guidelines on placenta accreta spectrum disorders: prenatal diagnosis and screening. Int J Gynaecol Obstet. 2018;140:274‐280.
Jauniaux E, Bhide A. Prenatal ultrasound diagnosis and outcome of placenta previa accreta after cesarean delivery: a systematic review and meta‐analysis. Am J Obstet Gynecol. 2017;217:27‐36.
Flores‐Mendoza H, Chandran AR, Hernandez‐Nieto C, et al. Outcomes in emergency versus electively scheduled cases of placenta accreta spectrum disorder managed by cesarean‐hysterectomy within a multidisciplinary care team. Int J Gynaecol Obstet. 2022;159:404‐411.

Auteurs

Petra Hanulikova (P)

Institute for the Care of Mother and Child, Third Faculty of Medicine, Charles University, Prague, Czech Republic.

Egle Savukyne (E)

Department of Obstetrics and Gynecology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania.

Karin A Fox (KA)

Division of Maternal-Fetal Medicine, Department of OB-GYN, Baylor College of Medicine, Houston, Texas, USA.

Lukas Sobisek (L)

Institute for the Care of Mother and Child, Third Faculty of Medicine, Charles University, Prague, Czech Republic.

Mina Mhallem (M)

Department of Obstetrics, Cliniques Saint-Luc, Brussels, Belgium.

Heleen J van Beekhuizen (HJ)

Department of Gynecological Oncology, Erasmus MC Cancer Center, Rotterdam, The Netherlands.

Vedran Stefanovic (V)

Department of Obstetrics and Gynecology, Fetomaternal Medical Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.

Thorsten Braun (T)

Department of Obstetrics, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.

Alexander Paping (A)

Department of Obstetrics, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.

Charline Bertholdt (C)

Department of Obstetrics, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.
Université de Lorraine, CHRU-NANCY, Pôle de la Femme, and Université de Lorraine, Inserm, IADI, Nancy, France., Nancy, France.

Olivier Morel (O)

Université de Lorraine, CHRU-NANCY, Pôle de la Femme, and Université de Lorraine, Inserm, IADI, Nancy, France., Nancy, France.

Classifications MeSH